```html

Factor V Leiden Thrombophilia – A Complete Patient Guide

Overview

Factor V Leiden thrombophilia (often shortened to “Factor V Leiden” or “FVL”) is an inherited genetic mutation that makes blood clot more easily than normal. The mutation affects the F5 gene, which encodes coagulation factor V—a protein that helps blood clot. In the Leiden variant, factor V becomes resistant to inactivation by activated protein C, leading to prolonged clotting activity.

• Who it affects: Both men and women can inherit the mutation. It is inherited in an autosomal dominant pattern, meaning a single abnormal copy of the gene can increase risk.
• Prevalence: Approximately 5% of people of European ancestry carry one copy (heterozygous) and about 0.05% are homozygous (two copies). In the United States, that translates to ~8–10 million heterozygous carriers and roughly 50 000–100 000 homozygotes.<sup>1</sup>
• Geographic variation: The mutation is rare in Asian and African populations (<1%) but common in northern European descendants.

Most carriers never develop a clot, but the mutation significantly raises the risk of venous thromboembolism (VTE) when combined with other risk factors (e.g., surgery, pregnancy, oral contraceptives).

Symptoms

Factor V Leiden itself does not produce symptoms; it predisposes individuals to clot‑related problems. When a clot forms, the following signs may appear.

Deep Vein Thrombosis (DVT)

• Swelling of the affected limb, usually the calf or thigh.
• Pain or tenderness that may feel like a cramp or soreness.
• Redness or warmth over the clot area.
• Visible surface veins (collateral circulation) may become more apparent.

Pulmonary Embolism (PE)

• Sudden shortness of breath.
• Sharp chest pain that worsens with deep breathing.
• Rapid heart rate (tachycardia) or palpitations.
• Light‑headedness, fainting, or coughing up blood‑tinged sputum.

Other Venous Thrombotic Events

• Portal vein thrombosis – abdominal pain, ascites.
• Cerebral venous sinus thrombosis – headache, visual changes, seizures.
• Pregnancy‑related clotting – placental insufficiency, pre‑eclampsia, miscarriage.

Because many clots can be silent, carriers often learn about their condition after a family member is diagnosed or after a clot event occurs.

Causes and Risk Factors

Genetic Basis

The single‑nucleotide substitution (G1691A) in the F5 gene creates the Leiden mutation. The altered factor V is less susceptible to deactivation, leading to a hypercoagulable state.

Inheritance Pattern

• Heterozygous (one mutated allele) – 5–7‑fold increased risk of VTE compared with the general population.
• Homozygous (two mutated alleles) – 50‑ to 80‑fold increased risk; often associated with recurrent clots.

Acquired Risk Factors that Amplify the Genetic Risk

• Major surgery or prolonged immobilization (e.g., long‑haul flights).
• Pregnancy and the postpartum period (up to 6 weeks).
• Hormone therapy – oral contraceptives, hormone replacement therapy.
• Obesity (BMI ≥ 30 kg/m²).
• Cancer and cancer‑directed chemotherapy.
• Central venous catheters or dialysis access.
• Inflammatory conditions (e.g., inflammatory bowel disease).

Diagnosis

Diagnosis rests on laboratory testing combined with a clinical assessment of clot history.

1. Genetic Testing

• Polymerase chain reaction (PCR) assay – Detects the G1691A mutation directly from blood or saliva.
• Results are reported as normal (no mutation), heterozygous, or homozygous.

2. Coagulation Screening (optional)

• Activated protein C resistance assay – Functional test showing how well factor V is inactivated; abnormal in most carriers.
• May be used when genetic testing is unavailable or for family screening.

3. Evaluation for Current Thrombosis

• Doppler ultrasound – First‑line imaging for suspected DVT.
• CT pulmonary angiography (CTPA) – Gold standard for pulmonary embolism.
• Magnetic resonance venography (MRV) – Used for cerebral or abdominal venous thrombosis.

When to Test

• Unexplained DVT/PE before age 50.
• Recurrent venous thrombosis.
• Family history of thrombophilia or early‑onset VTE.
• Pregnant women with personal or strong family clot history.

Treatment Options

Treatment aims to prevent clot formation, treat existing clots, and reduce recurrence risk. Management differs for heterozygous vs homozygous carriers and for the presence of an active clot.

1. Acute Clot Management

• Anticoagulation – Initial therapy with low‑molecular‑weight heparin (LMWH) or unfractionated heparin, followed by oral anticoagulants.
• Direct oral anticoagulants (DOACs) – Apixaban, rivaroxaban, edoxaban, or dabigatran are increasingly first‑line because they don’t require routine lab monitoring.
• Thrombolysis – Reserved for massive PE or limb‑threatening DVT; involves clot‑dissolving medication (e.g., alteplase).

2. Long‑Term Anticoagulation

• Duration – Typically 3–6 months after a first unprovoked DVT/PE. For recurrent events or homozygous carriers, lifelong anticoagulation may be recommended.
• Medication choices – Warfarin (target INR 2–3) or a DOAC. Warfarin requires INR monitoring and dietary vitamin K considerations; DOACs have fixed dosing and fewer interactions.

3. Prophylactic Strategies

• Peri‑operative prophylaxis – LMWH or DOACs started before and continued after surgery (typically 7–14 days, longer for high‑risk patients).
• Pregnancy – Low‑dose LMWH throughout pregnancy and the first 6 weeks postpartum is the standard for carriers with a prior clot or homozygous status.
• Birth control – Women should avoid estrogen‑containing pills or patches; progestin‑only options or a non‑hormonal device are safer.

4. Lifestyle and Adjunctive Measures

• Regular low‑impact exercise (e.g., walking, swimming) to improve circulation.
• Weight management – Reducing BMI <30 kg/m² lowers baseline VTE risk.
• Compression stockings (graduated, 20–30 mmHg) for those with previous DVT to prevent post‑thrombotic syndrome.

Living with Factor V Leiden Thrombophilia

Regular Monitoring

• If on warfarin – check INR at least weekly after initiation, then at stable intervals.
• If on a DOAC – routine labs are not required, but kidney function (eGFR) should be checked annually.
• Annual review with a hematologist or thrombosis specialist to reassess risk.

Travel Tips

• Stay hydrated; avoid alcohol and caffeine excess.
• Move legs every 1–2 hours (walking or calf‑raises).
• Consider wearing compression socks for flights >4 hours.
• Discuss with your doctor if you need temporary LMWH prophylaxis for long trips.

Pregnancy Planning

• Pre‑conception counseling with a maternal‑fetal medicine specialist.
• Early switch to LMWH rather than warfarin (which is teratogenic).
• Post‑delivery, continue LMWH for at least 6 weeks; many clinicians extend to 6 months if additional risk factors exist.

Family Communication

Because the mutation is hereditary, first‑degree relatives (parents, siblings, children) should be offered testing, especially if a clot event has occurred.

Prevention

• Maintain a healthy weight – Every 5 kg lost can reduce VTE risk by ~10%.
• Stay active – Aim for 150 minutes of moderate‑intensity aerobic activity per week.
• Avoid prolonged immobility – Use foot pumps or leg exercises during long surgeries or flights.
• Review medications – Discuss any new hormone therapy, chemotherapy, or anti‑platelet drugs with your provider.
• Vaccination – COVID‑19 and influenza infections can increase clot risk; stay up‑to‑date with vaccinations.
• Smoking cessation – Smoking doubles VTE risk and compounds the genetic predisposition.

Complications

If left untreated or inadequately managed, Factor V Leiden can lead to serious health problems.

• Recurrent venous thromboembolism – Each subsequent clot raises the risk of permanent vein damage.
• Post‑thrombotic syndrome – Chronic leg pain, swelling, skin discoloration, and ulceration after DVT.
• Chronic pulmonary hypertension – Repeated or large pulmonary emboli can damage lung vasculature.
• Pregnancy loss – Increased rates of miscarriage, stillbirth, and placental abruption.
• Fatal pulmonary embolism – Immediate death can occur with massive clot obstruction.

When to Seek Emergency Care

---

References
1. National Heart, Lung, and Blood Institute (NHLBI). “Factor V Leiden (F5) Gene.” https://www.nhlbi.nih.gov/health/factor-v-leiden
2. Mayo Clinic. “Factor V Leiden mutation.” https://www.mayoclinic.org/diseases-conditions/factor-v-leiden
3. CDC. “Venous Thromboembolism (Blood Clots).” https://www.cdc.gov/ncbddd/dvt/index.html
4. American College of Chest Physicians. “Antithrombotic Therapy for VTE Disease: 2024 Guidelines.” Chest. 2024;165(4):e91‑e123.
5. WHO. “Thrombosis and Haemostasis.” https://www.who.int/health-topics/thrombosis#tab=tab_1

```